Zenocutuzumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 01, 2026

Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.

Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.

Journal: Journal of gastrointestinal cancer

Published: June 27, 2026

The Evolving Role of Bispecific Antibodies in Oncogene-Driven NSCLC.

The Evolving Role of Bispecific Antibodies in Oncogene-Driven NSCLC.

Journal: Cancers

Published: June 22, 2026

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

Journal: International journal of molecular sciences

Published: April 08, 2026

Clinicopathologic Features of NRG1 Fusion-Positive Non-Small Cell Lung Cancer.

Clinicopathologic Features of NRG1 Fusion-Positive Non-Small Cell Lung Cancer.

Journal: Genes, chromosomes & cancer

Published: March 30, 2026

Advances in the clinical application of bispecific antibodies in cancer therapy.

Advances in the clinical application of bispecific antibodies in cancer therapy.

Journal: iScience

Published: January 01, 2026

Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions.

Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions.

Journal: Journal of immunotherapy and precision oncology

Published: November 26, 2025

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

Journal: Cancers

Published: October 29, 2025

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.

Journal: Journal of the National Cancer Institute

Published: October 13, 2025

COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling.

COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling.

Journal: Clinical and molecular hepatology

Published: September 26, 2025

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.

Journal: European journal of medical research

Published: September 16, 2025

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.

Journal: Oncology (Williston Park, N.Y.)

Published: August 20, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026